Overview

Clinical Efficacy and Safety Evaluation of Teneligliptin in Type 2 Diabetes Who Have Inadequate GlycemIc Control With Empaglyflozin and Metformin

Status:
Recruiting
Trial end date:
2025-03-31
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy and safety of teneligliptin 20 mg orally administered once daily for 24 weeks compared with placebo in patients with type 2 diabetes mellitus who have inadequate glycemic control with empaglyflozin and metformin
Phase:
Phase 3
Details
Lead Sponsor:
Handok Inc.